Skip to Content

'
Michelle A. Fanale, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

I have clinical and research interests in Hodgkin, T cell, Burkitt  lymphomas, & other c-MYC positive lymphomas, and HIV-associated lymphomas. Within these lymphoma subtypes I have a desire to develop new therapies which can first be evaluated in relapsed/refractory disease and then integrated into earlier lines of therapy both in combination with each other and with chemotherapy. I also wish to define best management strategies for the rarer disease presentations including for advanced stage and relapsed nodular lymphocyte predominant Hodgkin lymphoma, T cell lymphoma, and relapsed Burkitt and double-hit lymphomas. Through clinical trials I want to integrate translational research studies that will add to our understanding of mechanisms of lymphoma cell growth regulation and provide insights that will lead to improved methods of prognostication and combinations of therapies that target crucial pathways needed for lymphoma cell survival and proliferation.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 429
Houston, TX 77030
Phone: 713-792-2860
Fax: 713-794-5656
Email: mfanale@mdanderson.org

Education & Training

Degree-Granting Education

1999 University of Medicine and Dentistry, Newark, NJ, MD, MD
1994 Rutgers College, Rutgers University, New Brunswick, NJ, BA, Molecular Biology/Biochemistry and Psychology

Postgraduate Training

7/2002-6/2005 Medical Oncology and Hematology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert A. Wolff, M.D.
6/1999-6/2002 Internal Medicine Residency, Mayo Clinic, Rochester, MN, Henry J. Schultz, M.D.

Board Certifications

2006 American Board of Hematology
2005 American Board of Medical Oncology
2002 American Board of Internal Medicine

Experience/Service

Academic Appointments

Medical Oncologist, U.T. Memorial Hermann Hospital, Houston, TX, 4/2007-4/2008
Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2005-9/2012

Administrative Appointments/Responsibilities

Faculty Search Committee, Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, 8/2009-present

Other Appointments/Responsibilities

Co-Chair, North American Hodgkin Lymphoma Consortium, Houston, TX, 12/2015-present
Committee Member, NCI - Steering Committee for T-Cell Lymphoma, Bethesda, MD, 5/2014-present
Lymphoma Section Co-Chair, Academic and Community Cancer Research United (ACCRU), Rochester, MN, 1/2013-present
Scientific Advisor, Lymphoma Research Foundation (LRF), New York, NY, 1/2012-present
Committee Member, SWOG, Lymphoma Trials Working Group Committee, San Antonio, TX, 4/2010-present

Institutional Committee Activities

Member, Clinical and Translational Research Center (CTRC) Steering Committee, 9/2014-present
Member, Inpatient Operations Steering Real-Time Data Management (RTDM) Committee, 9/2014-present
Member, Meaningful Use Physician Steering Committee, 1/2013-present
Member, Institutional Review Board, 9/2011-present
Member, Pharmacy & Therapeutics Committee, 9/2011-8/2013
Member, Faculty Senate, 9/2010-present
Member, Credentials Committee of the Medical Staff, 9/2010-1/2013
Member, Growth Factor Task Force, 9/2006-present
Member, Clinical Research Committee, 9/2006-8/2008

Professional Memberships

American Society of Clinical Oncology (ASCO)
Member, 2003-present
American Society of Hematology (ASH)
Member, 2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Forero-Torres A, Hamadani M, Fanale MA, Bello Cm, Verhoef G, Gregory SA, Sonet A, Herbst R, Elgeioushi N, Li J, Eck S, Schneider A, Liang M, Ibrahim R, Goswami T, Cheson BD. Phase I study of MEDI-1551 (an anti-CD19 afucosylated humanized monoclonal antibody) in adults with relapsed or refractory advanced B-cell malignancies. Clinical Cancer Research, 5/2016.
2. Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. A US Intergroup Trial of Response-Adapted Therapy of Stage III–IV Hodgkin Lymphoma using Early Interim FDG–PET imaging (SWOG S0816). J Clin Oncol 34(12). e-Pub 4/11/2016. PMID: 27069074.
3. Fanale M. New Insights into NLPHL transformation. Blood 127(16):1946-1947, 4/2016. PMID: 27103741.
4. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol 34(2):160-8, 1/10/2016. e-Pub 11/30/2015. PMID: 26628470.
5. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic Stem Cell Transplantation in Patients With Cutaneous Lymphoma: Updated Results From a Single Institution. Ann Oncol 26(12):2490-5, 12/2015. e-Pub 9/28/2015. PMID: 26416896.
6. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 12/2015. e-Pub 9/2015. PMCID: PMC4715651.
7. Reddy JP, Akhtari M, Smith GL, Pinnix C, Osborne EM, Gunther JR, Allen PK, Yehia ZA, Fanale M, Rodriguez MA, Fowler N, Milgrom SA, Wogan CF, Dabaja BS. Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. Clin Lymphoma Myeloma Leuk 15(11):664-670.e2, 11/2015. e-Pub 8/5/2015. PMID: 26321471.
8. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant 21(11):1914-20, 11/2015. e-Pub 6/11/2015. PMID: 26071868.
9. Clemens MW, Collins MS, Butler CE, Hunt KK, Medeiros LJ, Fanale MA, Liu J, Miranda RN. Characteristics and Treatment of Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma Presenting with Aggressive Features. Plast Reconstr Surg 136(4 Suppl):119-20, 10/2015. PMID: 26397638.
10. Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. Ifosfamide, Carboplatin, Etoposide with or without bortezomib in Patients with Relapsed /Refractory Hodgkin Lymphoma: Results of a Randomized Phase II Trial. Leuk Lymphoma 57(2):445-447, 10/2015. e-Pub 3/2015. PMID: 25804933.
11. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes A. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol 169(5):689-93, 6/2015. e-Pub 3/2015. PMID: 25818067.
12. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol 169(6):814-23, 6/2015. e-Pub 3/31/2015. PMID: 25828695.
13. Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF. Comparison of Survival in Patients with T-cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. Biol Blood Marrow Transplant 21(5):855-9, 5/2015. e-Pub 1/31/2015. PMCID: PMC4408269.
14. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-82, 5/2015. PMCID: PMC4418193.
15. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by (18) fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 92(1):113-21, 5/2015. PMCID: PMC4418191.
16. Cheah CY, Belada D, Fanale MA, Janikova A, Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, Holden S, Seymour JF. Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomized study. Lancet Haematol 2(4):e166-74, 4/2015. e-Pub 3/2015. PMID: 26687959.
17. Forero-Torres A, Bartlett NL, Berryman RB, Chen R, Matous JV, Fanale MA, O'Connor OA, Olshefski R, Smith SE, Huebner D, Levine PL, Grove LE, Gopal AK. Extended Treatment with Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-positive Hematological Malignancies. Leuk Lymphoma 56(4):1-9, 4/2015. e-Pub 10/7/2014. PMID: 25110824.
18. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 3/2015. e-Pub 9/2014. PMCID: PMC4344896.
19. Cheah CY, Belada D, Fanale MA, Mayer J, Czucman MS, Portera CC, Ashkenazi A, Royer-Joo S, Seymour JF. A phase Ib/II study of dulanermin (rhAPO2L/TRIAL) with rituximab in patients with relapsed indolent B-cell lymphoma. Haematology, 1/2015.
20. Youssef B, Shank J, Reddy JP, Pinnix CC, Farha G, Akhtari M, Allen PK, Fanale MA, Garcia JA, Horace PH, Milgrom S, Smith GL, Nieto Y, Arzu I, Wang H, Fowler N, Rodriguez MA, Dabaja B. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiat Oncol 10(1):206, 2015. e-Pub 9/25/2015. PMCID: PMC4582821.
21. Fowler, NH, Davis, RE, Rawal, S, Nastoupil, L, Hagemeister, FB, McLaughlin, P, Kwak, LW, Romaguera, JE, Fanale, MA, Fayad, LE, Orlowski, RZ, Wang, M, Turturro, F, Oki, Y, Lacerte, L, Feng, L, Baladandayuthapani, V, Muzzafar, T, Tsai, KY, Samaniego, F, Neelapu, SS. Safety, Activity, and Immune Effects of Lenalidomide and Rituximab in Untreated Indolent Lymphoma. Lancet Oncology 15(12):1311-1318, 11/2014.
22. Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. (90) Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol 167(2):207-13, 10/2014. e-Pub 7/2014. PMID: 25040450.
23. Adrada BE, Miranda RN, Clemens MW, Rauch GM, Arribas E, Fanale M, Haideri N, Mustafa E, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: analysis of imaging studies in 44 patients reveals need for systematic assessment of mass versus no mass to improve diagnostic accuracy. Plast Reconstr Surg 134(4 Suppl 1):95-6, 10/2014. PMID: 25254804.
24. Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA. Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Lymphomas: A Retrospective Evaluation of Safety and Efficacy. Leuk Lymphoma 55(10):2328-34, 10/2014. e-Pub 2/2014. PMID: 24359243.
25. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study. J Clin Oncol 32(28):3137-43, 10/2014. e-Pub 8/2014. PMCID: PMC4171358.
26. Torres HA, Rallapalli V, Saxena A, Granwehr BP, Viola GM, Ariza-Heredia E, Adachi JA, Chemaly RF, Marfatia R, Jiang Y, Mahale P, Kyvernitakis A, Fanale MA, Mulanovich V. Efficacy and Safety of Antiretrovirals in HIV-Infected Patients with Cancer. Clin Microbiol Infect 10(20):O679-9, 10/2014. e-Pub 2/2014. PMID: 24529214.
27. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage program for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 10/2014. e-Pub 7/2014. PMID: 25039868.
28. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 9/2014. e-Pub 6/2014. PMID: 24943107.
29. Adrada BE, Miranda RN, Rauch GM, Arribas E, Kanagal-Shamanna R, Clemens MW, Fanale M, Haideri N, Mustafa E, Larrinaga J, Reisman NR, Jaso J, You MJ, Young KH, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat 147(1):1-14, 8/2014. e-Pub 7/30/2014. PMID: 25073777.
30. Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 7(1):24, 3/2014. e-Pub 3/2014. PMID: 24642247.
31. Fanale M, Assouline S, Kuruvilla J, Solal-Céligny P, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS. Phase IA/II, multicenter, open-label study of the CD40 antagonistic monoclonal antibody Lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol 164(2):258-65, 1/2014. e-Pub 11/2013. PMID: 24219359.
32. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 1/2014. e-Pub 12/2013. PMCID: PMC3922714.
33. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin Lymphoma. British Journal of Haematology 165(1):112-116, 04/2014, 1/2014. e-Pub 1/2014. PMID: 23486943.
34. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 19(24):6882-6890, 12/15/2013. e-Pub 10/4/2013. PMID: 24097867.
35. Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 14(13):1348-56, 12/2013. e-Pub 11/15/2013. PMID: 24239220.
36. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/1/2013. PMID: 24117234.
37. Arai S, Fanale M, DeVos S, Engert A, Illidge T, Borchmann P, Younes A, Morschhauser F, McMillan A, Horning SJ. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 54(11):2531-3, 11/2013. e-Pub 6/5/2013. PMID: 23617324.
38. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 9/2013. PMID: 23545991.
39. Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Biol Blood Marrow Transplant 19(6):991-4, 6/2013. PMID: 23507470.
40. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 4/2013. PMID: 23276888.
41. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 30(33):4161-7, 11/2012. PMID: 22965964.
42. Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A. Brentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin Lymphoma: analysis of two phases I studies. Oncologist 17(8):1073-80, 8/2012. PMCID: PMC3425525.
43. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. J Clin Oncol 30(22):2776-82, 8/2012. PMID: 22753910.
44. Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, Kwak LW, Neelapu SS. TCL1: A Shared Tumor-associated Antigen for immunotherapy Against B-cell Lymphomas. Blood 120(8):1613-23, 8/2012. PMCID: PMC3429305.
45. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 7/2012. PMID: 22677155.
46. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 6/2012. PMID: 22015451.
47. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. J Clin Oncol 30(18):2190-6, 6/2012. PMID: 22614995.
48. Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, Faria Sde C, Medeiros LJ, Ivy P, Younes A. Clinical Experience with the Heat Shock Protein-90 inhibitor, Tanespimycin (17AAG), in Patients with Relapsed Lymphoma. Leuk Lymphoma 53(5):990-2, 5/2012. PMID: 21988665.
49. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 5/2012. PMCID: PMC3359733.
50. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171-2, 3/2012. PMID: 22383790.
51. Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan (G-FM) as a reduced-intensity conditioning regimen for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma 53(3):499-502, 3/2012. e-Pub 10/2011. PMID: 21859247.
52. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL. A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clin Cancer Res 18(1):248-255, 1/2012. e-Pub 11/2011. PMID: 22080439.
53. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 12(13):1222-8, 12/2011. e-Pub 10/2011. PMID: 22033282.
54. Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 154(2):284-6, 7/2011. e-Pub 4/2011. PMID: 21517809.
55. Fanale MA, Younes A. Nodular lymphocyte predominant Hodgkin's lymphoma. Cancer Treat Res 142:367-81, 2008. PMID: 18283795.
56. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67(3)(3):333-350, 2007. PMID: 17335294.
57. Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK. Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther 13(8):806-14, 8/2006. e-Pub 4/2006. PMID: 16628227.
58. Fanale MA, Uyei AR, Theriault RL, Adam K, Thompson RA. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 6(4):354-6, 10/2005. PMID: 16277887.
59. McKenzie T, Liu Y, Fanale M, Swisher SG, Chada S, Hunt KK. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu overexpressing breast cancer cells. Surgery 136(2):433-437, 8/2004. PMID: 15300212.
60. Petersen WO, Trapp MA, Fanale MA, Kaur JS. Evaluating the WEB training program for cancer screening in Native American women. Holist Nurs Pract 17(5):262-75, 9/2003. PMID: 14596376.
61. Fanale MA, Zeldenrust SR, Moynihan TJ. Some unusual complications of malignancies: case 2. Marantic endocarditis in advanced cancer. J Clin Oncol 19(19):4111-4114, 10/2002. PMID: 12351608.
62. Ricketts MH, Amsterdam JD, Park DS, Yang RS, Poretz RD, Zhang X, Fanale M, Baddoo A, Manowitz P. A novel arylsulfatase A protein variant and genotype in two patients with major depression. J Affect Disord 40(3):137-47, 10/1996. PMID: 8897113.
63. Khouri, IF, Beitinjaneh, A, Saliba, RM, Medeiros, J, Turturro, F, Rondon, G, Korbling, M, Fayad, LE, Fanale, MA, Oki, Y, Alousi, AM, Anderlini, P, Oran, B, Hosing, C, Popat, UR, Champlin, RE, Pro, B. Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma, Including Lymphoblastic Subtype: A Single-Institution Experience with 188 Patients. Journal of Clinical Oncology. Submitted.
64. Dabaja B, Shihadeh F, Etzel C, Fu-Wen L, Shirvani S, Ballas L, Allen P, Rodriguez MA, Oki Y, Fanale M, Wogan C, and Younes A. Continuous Decline in Second Malignancies Occurring after Treatment of Hodgkin's Lymphoma: Analysis of 1670 Patients Seen Over a 50-year Period. Submitted.
65. Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, and Romaguera J. Oral Lenalidomide Plus 4 Doses of Rituximab Induces Prolonged Remissions in Relapsed/Refractory Mantle Cell Lymphoma: A Phase I/II Clinical Trial. Journal of Oncology. Submitted.
66. Fanale MA, Whiting NC, Neylon E, Mellon-Reppen S, Bader B, Exter B, Forero-Torresf A. Treatment Strategies to Optimize Outcomes with Brentuximab Vedotin: Management of Common and Rare Toxicities to Enhance Patient Care. The International Journal of Targeted Therapies in Cancer. Submitted.

Invited Articles

1. Cheah CY, Oki Y, Fanale MA. Novel treatments for T-cell Lymphoma. Am Soc Clin Oncol Educ Book:e468-78, 2015. PMID: 25993211.
2. Fanale M. A novel prognostic scoring system for NLPHL. Blood 122(26):4154-5, 12/19/2013. PMID: 24357707.
3. Fanale M. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment? Hematology Am Soc Hematol Educ Program 2013:406-13, 2013. PMID: 24319212.

Editorials

1. Fanale, M. Hortobagyi, G. Bisphosphonates in the prevention and treatment of bone metastases. Oncology(17):1278-1280, 2003.

Abstracts

1. Reddy JP, Akhtari M, Smith GL, Pinnix C, Osborne EM, Gunter JR, Allen PK, Yehia ZA, Fanale M, Rodriguez MA, Fowler N, Milgrom S, Wogan CF, Dabaja BS. Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma with Bulky Disease. Clinical Lymphoma, Myeloma & Leukemia 15(11):664, 11/2015.
2. Cheah CY, Chihara D, Sevin A, Horowitz S, Oki Y, Fowler N, Neelapu S, Nastoupil L, Turturro F, Hagemeister F, Westin J, Romaguera J, Fayad L, Samaniego F and Fanale MA. Patients with Classical Hodgkin Lymphoma Failing Brentuximab Vedotin have Brief Responses to Salvage Therapies and Limited Survival. HAA Annual Scientific Meeting 2015 (#644), 10/2015.
3. Clemens MW, Butler CE, Hunt K, Fanale MA, Horwitz SM, Liu H, McCarthy C, Nastoupil LJ, Liu J, Medeiros LJ, Miranda RN. Breast Implant-Associated Anaplastic Large Cell Lymphoma: Proposal for Optimal Management. J Clin Oncol 33 (#8550), 5/2015.
4. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook FS, Piha-Paul SA, Wheler JJ, Hong DS, Subbiah V, Tsimberidou AM, Kaseb AO, Oki Y, Zinner R, Patel S, Velez Bravo VM, Fanale MA, Meric-Bernstam F, Kurzrock R, Janku F. Phase I Study of the mTOR Inhibitor Sirolimus and the HDAC Inhibitor Vorinostat in Patients with Advanced Malignancies. J Clin Oncol 33 (#2584), 5/2015.
5. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad L, Romaguera JE, Samaniego F, Neelapu S, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II Study of Hyper-CVAD with Pegylated Liposomal Doxorubicin Alternating with Methotrexate and Cytarabine (HCVIDD/MA) in Patients with Newly Diagnosed T- and NK-cell Lymphoma (T/NKCL). J Clin Oncol 33 (#8538), 5/2015.
6. Liang WS, Salhia B, Helland A, Sekar S, Garrido-Laguna I, Fanale M, Oki Y, Westin JR, Davis RE, Meric-Bernstam F and Janku F. Identification of Mutations in Histone Modification Genes in Hodgkin Lymphoma. American Association of Cancer Research (AACR 106th Annual Meeting 2015) 75 (15) (#LB-176), 4/2015.
7. Sakamuri D, Betancourt Cuellar SL, Glitza IC, Fu S, Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Subbiah V, Fanale MA, Cabanillas ME, Meric-Bernstam F and Janku F. Phase 1 Study: Ipilimumab (anti CTLA-4) in Combination with Lenalidomide in Patients with Advanced Cancers. American Association of Cancer Research (AACR 106th Annual Meeting 2015) 75 (15) (#246), 4/2015.
8. Fanale, MA, Hagemeister, FB, Fayad, L, Oki, Y, Fowler, N, Romaguera, J, Shah, N, Chuang, H, Feng, L, Horowitz, S, Wesson, E, Hutto, Muzzafar, T, Samaniego, F, Davis, RE. A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas. Blood 124(21) (#Abstr. #1744; 624), 12/2014.
9. Connors, JM, Ansell, S, Park, SI, Fanale, MA, Younes, A. Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma: Long Term Outcomes. Blood 124(21) (#Abstr. #292; 624), 12/2014.
10. Pro, B, Advani, R, Brice, P, Bartlett, NL, Rosenblatt, JD, Illidge, T, Matous, J, Ramchandern, R, Fanale, MA, Connors, J, Wang, Y, Huebner, D, Kennedy, DA, Shustov, AR. Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood 124(21) (#Abstr. #3095; 624), 12/2014.
11. Moskowitz, CH, Forero-Torres, A, Shah, BD, Advani, R, Hamlin, P, Kim, S, Kostic, A, Sandalic, L, Zhao, B, Fanale, MA. Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma. Blood 124(21), 12/2014.
12. Chihara, D, Oki, Y, Fayad, L, Wesson, E, Ruben, C, Horowitz, SB, Woolery, J, Feng, L, Garg, N, Ahmed, S, Khouri, IF, Fanale, MA. Phase I Study of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood 124(21) (#Abstr #1748; 624), 12/2014.
13. Nastoupil, LJ, Neelapu, SS, Samaniego, F, Hagemeister, FB, Romaguera, JE, Kwak, LW, Wang, M, Fayad, L, Fanale, MA, Oki, Y, Westin, JR, Rodriguez, MA, Cabanillas, F, McLaughlin P, Fowler, NH. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. J Clin Oncol 32(8528), 5/2014.
14. Janku, F, Oki, Y, Falchook, GS, Subbiah, V, Naing, A, Velez Bravo, VM, Hong, DS, Westin, JR, Nunez, C, Fayad, L, Neelapu, SS, Kwak, LW, Shpall, EJ, Wheler, JJ, Barnes, T, Liang, WS, Salhia, B, Meric-Bernstam, F, Kurzrock, R, Fanale, MA. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. J Clin Oncol 32(8508) (#8508), 5/2014.
15. Forero-Torres, A, Moskowitz, C, Advani, RH, Shah, BD, Kostic, A, Albertson, TM, Sandalic, L, Zhao, B, Fanale, MA. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin Lymphoma (NHL). J Clin Oncol 32(8505) (#8505), 5/2014.
16. Oki, Y, Fanale, MA, Westin, JR, Fowler, N, Neelapu, SS, Hagemeister, FB, Rodriguez, MA, Younes, A. A Phase I Study Of Panobinostat In Combination With ICE (Ifosfamide, Carboplatin and Etoposide) In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL). Blood 122(21), 12/2013.
17. Fanale, MA, Horwitz, SM, Forero-Torres, A, Bartlett, NL, Advani, RH, Pro, B, Chen, R, Davies, A, Illidge, T, Huebner, D, Kennedy, DA, Shustov, AR. Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. Blood 122(21), 12/2013.
18. Oki, Y, Noorani, M, Davis, RE, Neelapu, SS, Rodriguez, A, Hagemeister, FB, Fowler, N, Wang, M, Fanale, MA, Samaniego, F, Dabaja, BS, Pinnix, C, Kwak, LW, Romaguera, JE, Khouri, I, Westin, JR, Fayad, LE,. Double Hit Lymphoma: M.D. Anderson Experience. Blood (#1776; 622), 12/2013.
19. Anderlini, P, Saliba, RM, Ledesma, C, Chancoco, CM, Alexander, T, Alousi, A, Hosing, CM, Khouri, I, Nieto, Y, Popat, UR, Shpall, EJ, Fanale, MA, Oki, Y, Romaguera, JE, Neelapu, S, Younes, A, Champlin, RE. Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). Blood 122(21) (#410), 12/2013.
20. Forero-Torres, A, Hamadani, M, Fanale, MA, Bello, CM, Kipps, TJ, Offner, F, Verhoef, G, Federico, M, Gregory, SA, Sonet, A, Assouline, S, Pérez de Oteyza, J, Tomas, JF, Cuneo, A, Elgeioushi, N, Goswami, T, Ibrahim, R, Herbst, R, Cheson, BD. Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies. Blood 122(21) (#1810; 624), 12/2013.
21. Janku, F, Garrido-Laguna, I, Velez-Bravo, V, Falchook, GS, Subbiah, V, Hong, DS, Oki, Y, Westin, JR, Nunez, CA, Fayad, LE, Kwak, LW, Shpall, EJ, Wheler, JJ, Liang, W, Salhia, B, Meric-Bernstam, F, Kurzrock, R, Fanale, M. Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Blood 122(51), 12/2013.
22. Pro, B, Advani, RH, Brice, P, Bartlett, NL, Rosenblatt, JD, Illidge, T, Matous, J, Ramchandren, R, Fanale, MA, Connors, JM, Yang, Y, Huebner, D, Kennedy, DA, Shustov, AR. Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood 122(21) (#1809), 12/2013.
23. Nieto, Y, Thall, PF, Valdez, BC, Hosing, CM, Ahmed, S, Jones, RB, Shah, N, Anderlini, P, Qazilbash, MH, Popat, UR, Bashir, Q, Shpall, EJ, Alousi, A, Kebriaei, P, Fox, P, Bassett, R, Chancoco1, C, Oki, Y, Fanale, MA, Fowler, N, Hagemeister, F, Romaguera, JE, Champlin, RE, Andersson, BS. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. Blood 122(21) (#2095; 731), 12/2013.
24. Oki, Y, Neelapu, SS, Fanale, MA, Kwak, LW, Fayad, LE, Rodriguez, A, Wallace, M, Carlton, V, Kong, K, Faham, M, Younes, A. Detection Of Classical Hodgkin Lymphoma In Peripheral Blood Using High-Throughout Sequencing Assay. Blood 122(21) (#627), 11/2013.
25. Patel, K, Feng, L, Oki, Y, Qazilbash, M, Muzzafar, T, Weber, DM, Fowler, N, Popat, UR, Thomas, SK, Fanale, MA, Nieto, Y, Shah, N, Bashir, Q, Hagemeister, FB, Orlowski, RZ, Shah, JJ. Plasmablastic Lymphoma: 28 Patient Single Institution Experience. Blood 122(21) (#4310), 11/2013.
26. Samaniego F, Wise J, Fayad L, Fanale M, Hagemeister F, Sevaraj V, Goldenberg D, Kwak L, Berkova Z. Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo. Blood 118(21) (#1796), 11/2012.
27. Fanale MA, Shustov AR, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Kennedy DA, Horwitz SM. Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. Blood 120(21):60, 11/2012.
28. Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak L, Romaguera J, Fanale M, Fayad L, Orlowski R, Wang M, Turturro F, Oki Y, Lacerte L, and Samaniego F. Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a phase I/II study. Blood 120(21) (#901), 11/2012.
29. Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T, Matous J, Ramchandren R, Fanale M, Connors J, Yang Y, Kennedy D, and Shustov A. Long-term remissions observed in an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 120(21) (#2745), 11/2012.
30. Forero-Torres A, Hamadani M, Fanale M, Bello C, Kipps T, Offner F, Verhoer G, Federic M, Gregory S, Sonet A, Assouline S, Oteyza J, Tomas J, Cuneo A, Zhang W, Goswani T, Ibrahim R, Yao Z, Herbst R, and Cheson B. MEDI-551, a humanized monoclonal anti-CD19, in adults with relapsed or refractory advanced B-cell malignancies: Results from a Phase I/II study. Blood 120(21) (#3677), 11/2012.
31. Fanale M, Bensinger W, Byrd J, Ewald B, Carreon D, Baeck J, Freedman A. Multi-trial Safety Evaluation of the Fully Antagonistic, Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-cell Malignancies. Blood 120(21), 11/2012.
32. Karaturi M, Arai S, Chen R, Gopal A, Feng L, Yuan Y, Smith S, Ansell S, Rosenblatt J, Savage K, Ramchandren R, Barlett N, Cheson B, Forero-Torres A, Moskowitz C, Connors J, Fanale M, de Vos S, Engert A, Illidge T, Borchmann P, Morschhauser F, Horning S, and Younes A. Overall survival benefit for patients with relapsed Hodgkin lymphoma treated with brentuximab vedotin after autologous stem cell transplant. Blood 120(21) (#3701), 11/2012.
33. Westin J, Chu F, Fayad L, Kwak L, Fowler N, Romaguera J, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu S. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. Blood 120(21) (#793), 11/2012.
34. Fanale M, Lai C, Rimes S, Ramirez M, Hagemeister F, Fowler N, Younes A, Fayad L, Rodriguez MA, Turturro F, Samaniego F, Romaguera J, Levin V, Horowitz S, Woolery J, and Milbourne A. Positive maternal-fetal outcomes with treatment of lymphoma during pregnancy: UT MD Anderson Cancer Center prospective experience. Blood 120(21) (#3670), 11/2012.
35. Oki Y, Westin J, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak L, Romaguera J, Fanale M, Younes A, Rodriguez MA, Orlowski R, Wang M, Ouzounian S, Samaniego F, and Fayad L. R-HCVAD alternating with R-methotrexate cytarabine in younger patients (pts) with IH and high-risk age adjusted-IPI DLBCL. Blood 120(21) (#3707), 11/2012.
36. Fanale M, Bartlett N, Forero-Torres A, Younes A, Chen R, Friedberg J, Matous J, Shustov A, Smith S, Zain J, O-Meara M, and Gopal A. Retrospective analysis of the safety and efficacy of brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30+ hematologic malignancies. Blood 120(21) (#3687), 11/2012.
37. Oki Y, Chuang H, Chasen B, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister FB, Rodriguez A, Neelapu S, Samaniego F, Kwak L, and Younes A. The prognostic value of interim PET scan in patients with classical Hodgkin lymphoma. Blood 120(21) (#1529), 11/2012.
38. Advani R, Fanale M, Kennedy D, Pro B. Resolution of Malignant Cutaneous Lesions with Brentuximab Vefotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (sALCL), 3/2012.
39. Advani, R, Shustov A, Matous J, Radhakrishnan Ramchandren R, Fanale M,Connors, J, Yang, YKennedy D andPro B. Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. Blood 118(21) (#443), 11/2011.
40. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera J, Fanale M, Fayad L, Fowler N, Huen A, Hagemeister F, Rodriguez A, Neelapu S, Samaniego F, Younes A, Kwak L. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, +/- Rituxan (R/CHOP): Randomized, Double-blind, Placebo-Controlled Study. Blood 118(21) (#1613), 11/2011.
41. Fowler N, Neelapu S, Fanale M, Rodriguez M, Pro B, Hagemeister F, Younes A, Shah J, Kwak L, Rodriguez D, McLaughlin P. Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma. Blood 118(21) (#99), 11/2011.
42. Fanale M, Franklin A, Ramchandren R, Termuhlen A, Gopal AK, Shustov A, Kennedy D, Sievers E. Complete remissions observed in a subset of pediatric patients with CD30-Expressing malignant lymphomas treated in clinical studies of brentuximab vedotin (SGN-35). 2011 The European Multidisciplinary Cancer Congress (#9201), 9/2011.
43. Shustov AR, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale MA, Connors JM, Yang Y, Sievers EL, Kennedy DA, Pro Bi. Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase 2 study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). 11th International Conference on Malignant Lymphoma, 6/2011.
44. Advani R, Forero-Torres A, Fanale M, Bartlett N, Rosenblatt J, Kennedy D, Sievers E, Younes A. Objective responses with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin Lymphoma (HL) who refused or were ineligible for autologous stem cell transplantation (ASCT). 16th Congress of the European Hematology Association, 6/2011.
45. Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, and Romaguera J. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: a completed phase I/II clinical trial. 11th International Conference on Malignant Lymphoma 22(Suppl 4), 6/2011.
46. Romaguera J, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad L, Fowler N, Orlowski R, Feldman T, Wagner-Bartak N, Smith J, Ford P, Kwak L, and Goy A. Phase I-II study of bortezomib in combination with R-HCVAD and R-Methotrexate/cytarabine (R-MA) in untreated mantle cell lymphoma (MCL). 11th International Conference in Malignant Lymphoma, 6/2011.
47. Advani R, Fanale M, Kennedy D, Pro B. Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. American Academy of Dermatology 2012, 6/2011.
48. Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T, Matous J, Ramchadren R, Fanale M, Connors J, Yang Y, Sievers E, Kennedy D and Shustov A. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. 2011 T-Cell Lymphoma Forum, 1/2011.
49. Freedman A, Kuruvila J, Assouline S, Engert A, Heo D, Solal-Celigny P, Corradini P, Verhoef G, Fanale M, Bendiske J, Ewald B, Dey J, Baeck J, and Younes A. Clinical activity of lucatumumab (HCD122) in patients (pts) with relapsed/refractory Hodgkin or Non-Hodgkin lymphoma treated in a phase Ia/II clinical trial (NCT00670592). Blood, 12/2010.
50. Shustov A, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T, Matous J, Ramchadren R, Fanale M, Connors J, Yang Y, Sievers E, Kennedy D, and Pro B. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood, 12/2010.
51. Fanale M, Lai C, McLaughlin P, Romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez M, Neelapu S, Shah J, Kwak L, Dong W, Reed V, Dabaja B, Popat U, and Younes A. Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. Blood, 12/2010.
52. Younes A, Fanale M, McLaughlin P, Copeland A, Zhu J, and de Castro S. Phase I study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: Evidence of clinical and biologic activity in multiple lymphoma subtypes. Blood, 12/2010.
53. Younes A, Copeland A, Fanale M, Hagemeister F, Fayad L, Pro B, Faria S, Ji Y, Medeiros J, Berry D, and Buglio D. Phase I/II study of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and Non-Hodgkin lymphoma. Blood, 12/2010.
54. Vadhan-Raj S, Hagemeister F, Fayad L, Zhou X, O'Roark S, Ames K, Rodriguez M, Fanale M, Pro B, Johnson M, McLaughlin P, Bueso-Ramos C, Younes A, Kwak L, and Romaguera J. Randomized, double-blind, placebo-controlled, dose and schedule-finding study of AMG 531 in chemotherapy-induced thrombocytopenia (CIT): Results of a phase I/II study. Blood 116(21), 12/2010.
55. Fanale M, Fayad L, Kwak L, Liboon MJ, Horowitz S, Nieto Y, Anderlini P, Popat U, and Younes A. A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus ICE for Patients with Relapsed or Refractory Hodgkin Lymphoma. 8th International Symposium on Hodgkin Lymphoma (#94), 10/2010.
56. Fanale M, Vigil K, Nieto Y, Younes A, and Mulanovich V. Increased Risk of Infectious Complications in HIV Patients with Advanced Stage and Relapsed Hodgkin Lymphoma. 8th International Symposium on Hodgkin Lymphoma (#95), 10/2010.
57. Fowler N, McLaughlin P, Hagemeister FB, Kwak LW, Fanale, MA Neelapu SS, Fayad L, Orlowski RZ, Wang M, and Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 28(15 Suppl):8036a, 5/2010.
58. Fowler N, McLaughlin P, Hagemeister F, Kwak L, Fanale M, Neelapu S, Fayad L, Pro B, Sergent C, White S, Samaniego F. A biologic combination of lenalidomide and rituximab for frontline therapy of indolent B-cell non-Hodgkin's lymphoma. Blood 114(22):683, 11/2009.
59. Wang M, Fayad L, Hagemeister F, Neelapu S, Samaniego F, McLaughlin P, Samuels b, Yi Q, Pro B, Fanale M, Shah J, Younes A, Bell N, Knight R, Zeldis J, Kwak L, Romaguera J. A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma. Blood 114(22):1064, 11/2009.
60. Popat U, Hosing C, Fanale M, Medeiros J, Alousi A, Giralt S, de Lima M, Qazilbash M, Kebriaei P, Younes A, Khouri I, Anderson B, Champlin R, Anderlini P. Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Blood 114(22):912, 11/2009.
61. Westin J, Thompson M, Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone loss in frontline lymphoma patients: urine Ntx and bone specific alkaline phosphatase provide early evidence of zoledronic acid activity. Blood 114(22):1508, 11/2009.
62. Younes A, Copeland A, Romaguera J, Fayad L, Fanale M, Faria S, Medeiros J, Ivy P. Clinical and Biological Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma. Blood 114(22):1441, 11/2009.
63. Copeland A, Cao Y, Fanale M, Fayad L, McLaughlin P, Pro B, Hagemeister F, Romaguera J, Samaniego F, Rodriguez A, Younes A. Final report of a phase II study of rituximab plus ABVD for patients with newly diagnosed advanced stage classical Hodgkin's lymphoma: results of long follow up and comparison to institutional historical data. Blood 114(22):670, 11/2009.
64. Younes A, Gordon L, Kim S, Romaguera J, Copeland A, Faria S, Kwak L, Fayad L, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Blood 114(22):243, 11/2009.
65. Younes A, Fanale M, McLaughlin P, Copeland A, Faria S, Hart S, Jayaraman R, Zhu J. Phase-I study of the novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biological activity. Blood 114(22):244, 11/2009.
66. Vadhan S, Fayad L, Fanale M, Rodriguez A, Hagemeister F, Ames K, Bueso-Ramos C, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, Romaguera J. Randomized clinical trial of rasburicase administered as a standard fixed five days dosing vs a single dose followed by as needed dosing in adult patients with hematologic malignancies at risk for developing tumor lysis syndrome. Blood 114(22):48, 11/2009.
67. Fanale M, Bartlett N, Forero-Torres A, Rosenblatt J, Horning S, Thompson S, Franklin A, Sievers EL, Kennedy DA. The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study. Blood 114(22):1068, 11/2009.
68. Fanale M, Stiff P, Noonan K, McCoy J, Rustein M, and Moskowitz C. Safety and efficacy of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose and schedule-finding study. European Journal of Cancer Supplements 7(2):562, 9/2009.
69. Bartlett, N.L., Forero-Torres, A., Rosenblatt, J., Fanale, M., Horning, S., Thompson, S., Kennedy, D., Sievers, E. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin Lymphoma (HL) or anaplastic large cell lymphoma (ALCL). J Clin Oncol 27(15S):Suppl 1 (#8500), 5/2009.
70. Fowler, N.H., McLaughlin, P., Kwak, L., Hagemeister, F., Fanale, M., Fayad, L., Pro, B., Samaniego, F. Lenalidomide and Rituximab for untreated indolent B cell non-Hodgkin lymphoma. J Clin Oncol 27(15S):Suppl 1 (#8548), 5/2009.
71. Samaniego, F., Fanale, M., Pro, B., Hagemeister, F.B., McLaughlin, P., Romaguera, J., Neelapu, S., Rodriguez, M.A., Fayad, L., Younes, A., Kwak, L. Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B Cell Lymphoma without Prolonged Myelosuppression. Blood(835), 12/2008.
72. McLaughlin, P., Neelapu, S., Fanale, M., Rodriguez, D., Ayala, A., Pro, B., Hagemeister, F. B., Younes, A., Neel, S., Fowler, N., Hess, M., Kwak, L. R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma. Blood(3056). e-Pub 12/2008.
73. Fanale M., Fayad, L.E., Pro, B., Samaniego, F., Zachariah, G., Nunez,C.A., Ji, Y., Younes, A. A phase I evaluation of bortezomib in combination with ICE (BICE) as treatment for relapsed/refractory classical Hodgkin lymphoma. 10th International Conference on Malignant Lymphoma(531), 6/2008.
74. Horning, S., Fanale M., deVos, S., Borchmann, P., Illidge, T., Engert, A., Arai, S., Younes, A. Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort. 10th International Conference on Malignant Lymphoma(118), 6/2008.
75. Fanale, M., Burris, H., Yee, L., Luca, J., Dimick, K., Goldwasser, M., Novotny, W., Bray, G. Final results of a Phase Ib study of recombinant human Apo2L/TRAIL with rituximab in patients with relapsed low-grade NHL. 10th International Conference on Malignant Lymphoma(258), 6/2008.
76. Samaniego, F., Pro, B., Nunez, R., McLaughlin, P., Fanale, M., Kwak, L., Romaguera, J. High Response Rates for Stage I Indolent B-Cell Lymphoma with Yttrium-90 Ibritumomab Tiuxetan (Zevalin). 10th International Conference Malignant Lymphoma(422), 6/2008.
77. Samaniego, F., Fanale, M., Pro, B., Hagemeister, F., McLaughlin, P., Romaguera, J., Neelapu, S., Younes, A., Kwak, L. Pentostatin Combined with Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B Cell Lymphoma. 10th International Conference of Malignant Lymphoma(334), 6/2008.
78. Fanale, M.A., Fayad, L., Pro, B., Samaniego, F., Zachariah, G., Nunez, C.A., Ji, Y., Younes. A phase I study of bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma. Blood(3048), 2008.
79. Rodriguez, M.A., Fanale, M., Hagemeister, F.B., McLaughlin, P., Pro, B., Romaguera, J., Kwak, L., Fayad, L.E., Durand, J. Activity and toxicity of pegylated liposomal doxorubicin (DRCOP) for patients >60 years old with untreated diffuse large B cell lymphoma (DLBCL) : A phase II study. J Clin Oncol 26(15S/20505), 2008.
80. Huen, A., DeAngelo, D., Fanale, M., Vadhan-Raj, S. Pharmacokinetic analysis of two dose levels of rasburicase in adult patients with hematologic malignancies at high or potential risk for tumor lysis syndrome. J Clin Oncol 26(15S/14545), 2008.
81. Samaniego F., Fanale M., Pro B. Hagemeister F., McLaughlin P., Romaguera J., Neelapu F., Rodriguez A., Fayad L., Younes A., Beasley G., Kwak L. A Phase II trial of pentostatin combined with cyclophosphamide, and rituximab (PCR) for indolent B-cell lymphoma, American Society of Hematology. Blood 110(11), 11/2007.
82. Younes A., Pro, B., Fanale M., McLaughlin P., Neelapu S., Fayad L., Wedgwood A., Buglio D., Patterson T., Dubay M., Zuomei L., Martell R., Ward M., Bociek R. Isotype-selective HDAC inhibitor MGCD0103 decreases. Blood 110(2566), 11/2007.
83. Rodriguez M.A., Fanale M., Hagemeister F., McLaughlin P., Pro B., Romaguera J., Kwak L., Fayad L., Huang X., Durand J.B. Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients > 60 years old with untreated diffuse large B cell lymphoma (DLBCL). Blood 110(4468), 11/2007.
84. Fanale M., Fayad L., Pro B., Samaniego F., Zachariah G., Ji Y., Younes A. Safety and efficacy of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory classical Hodgkin Lymphoma. Blood 110(4506), 11/2007.
85. Yee L., Fanale M., Dimick K., Calvert S., Robins C., Ing J., Ling J., Novotny W., Ashkenazi A., Burris III H. A Phase IB safety and pharmacokinectic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. J Clin Oncol 25(2078) (#2078), 2007.
86. Younes A, Fanale M., Pro B., McLaughlin P., Neelapu S., Fayad L.,. A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol 25(8000), 2007.
87. Gilliam M., Fanale M., Patterson C. Effectiveness of gonadotropin-releasing hormone agonists in prevention of ovarian failure in Hodgkin lymphoma: Update on current practice and review of literature. 7th International Symposium on Hodgkin Lymphoma 95(55):056, 2007.
88. Gilliam M., Wedgwood A., Fanale M. Effectiveness of lamivudine in the prevention of hepatitis B reactivation in patients receiving rituximab. Pan Pacific Lymphoma Conference, 2007.
89. Fanale M., Fayad, L.E., Romaguera J.E., McLaughlin P., Hagemeister. Experience with R-CHOP in patients with lymphocyte predominant Hodgkin lymphoma (LPHL). 7th International Symposium on Hodgkin Lymphoma 92(55):077, 2007.
90. Samaniego F, Fayad L. E. Pro M., McLaughlin P., Rodriguez M.A., Hagemeister F.B., Fanale M., Neelapu S., Younes A., Kwak L.W. Pentostatin combined with cyclophosphamide, and rituximab induces high response rates in patients with untreated indolent B-cell lymphoma. Blood 108(4722), 2006.
91. Younes A., Fayad L., Goy A., McLaughlin P, Pro B., Romaguera J, Hagemeister F., Rodriguez M.A., Samaniego F., Kwak L., Neelapu S., Medeiros L.J., Wedgwood A., Fanale M. Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups. Blood 108(2742), 2006.
92. Fanale M., Vorburger S., Liu Y., McKenzie T., Swisher S., Hunt K. AdhTERT-E2F-1 can induce selective apoptosis of breast cancer cells through multiple mechanisms. American Association of Cancer Research 46(2834), 2005.
93. McKenzie T.S., Lui Y., Keyomarsi K., Holzen U.V., Suh, Y., Fanale M., Swisher S., Chada S., and Hunt K. Associated gene-7 (Ad-mda7) regulated the Wnt signaling pathway in breast cancer cells. American Association of Cancer Research:871, 2005.
94. Fanale M., Liu Y., McKenzie T., Fokt I., Priebe W., Hunt K. Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline. J Clin Oncol 24(2082), 2005.
95. Fanale M., Liu Y., McKenzie T., Fokt I., Priebe W., Hunt K. A novel anthracycline highly apoptotic in breast cancer cells. American. American Association of Cancer Research 45(3843), 2004.
96. McKenzie T., Liu Y., Fanale M., Swisher S., Chada S., Hunt K. Combination therapy of Ad-mda7 and trastuzumab inhibits tumor growth in nude mice and increase apoptosis in Her-2/neu overexpressing breast cancer cells. American Association of Cancer 45(5135), 2004.
97. Fanale M., Liu Y., McKenzie T., Fokt I., Priebe W., and Hunt K. Experimental and molecular therapeutics 35: preclinical models/pharmacology/mechanisms. American Association of Cancer Research:887, 2004.
98. Liu Y., McKenzie T., Fanale M., Swisher S., Chada S., Hunt K. Increased apoptosis in Her-2/neu overexpressing breast cancer cells by combination of Ad-mda7 and Herceptin. American Association of Cancer Research 45(4402), 2004.
99. Fanale M., Liu Y., McKenzie T., Vorburger S., Swisher S., Theriault R., Hunt K. Utility of hTERT-driven overexpression of E2F-1 to induce selective apoptosis of human breast cancer cells. American Society of Clinical Oncology 23(3158), 2004.

Book Chapters

1. Chihara D, Hagemeister FB, Fanale M. Hodgkin Lymphoma. In: MD Anderson Cancer Center: Medical Oncology, A Comprehensive Review, 3rd, 2015.
2. Eichenauer D, Fanale M. Lymphocyte-Predominant Hodgkin Lymphoma. In: Hodgkin Lymphoma: A Comprehensive Overwrite, First. Ed(s) Springer. Springer, 2015.
3. Fanale M, Dabaja B, Popat U, Anderlini P, Younes A. Hodgkin Lymphoma. In: 60 years of Survival Outcomes at the University of Texas MD Anderson Cancer Center. Springer, 2013.
4. Westin J, Hagemeister F, Reed V, Fanale M. Hodgkin Lymphoma. In: MD Anderson Cancer Center: Medical Oncology, A Comprehensive Review, Second. McGraw-Hill, 2011.
5. Fanale M, Younes A. Diagnosis and treatment of lymphocyte predominant Hodgkin lymphoma. In: Rare Hematological Malignancies. Ed(s) Springer. Springer, 2007.
6. Fanale M, Buzdar A. Treatment of early-stage, locally advanced, and inflammatory breast cancer. In: MDACC: Medical Oncology, A Comprehensive Review, First. Ed(s) McGraw-Hill, 2007.

Manuals, Teaching Aids, Other Teaching Publications

1. Fanale, M. Burkitt's Lymphoma Management Algorithm. MDACC Lymphoma Department Website: Houston, TX, 9/2014.
2. Fanale, M. Hodgkin Lymphoma Survivorship Algorithm. MDACC Lymphoma Department Website: Houston, TX, 9/2014.
3. Fanale, M. T-cell Lymphoma Survivorship Algorithm. MDACC Lymphoma Department Website: Houston, TX, 9/2014.
4. Fanale, M. Hodgkin Lymphoma Survivorship Algorithm. MDACC Lymphoma Department Website: Houston, TX, 9/2012.
5. Fanale M. Burkitt's Lymphoma Management Algorithm. MDACC Lymphoma Department Website: Houston, TX, 9/2011.
6. Fanale M. HIV-associated Lymphoma Management Algorithm. MDACC Lymphoma Department Website: Houston, TX, 9/2011.

Grant & Contract Support

Title: High Impact Clinical Research Support Program (Hi-CRSP)
Funding Source: UT MD Anderson Cancer Center
Role: Principal Investigator
Duration: 9/2014 - present
 
Title: Moon Shot Program, B-Cell Lymphoma
Funding Source: MD Anderson Cancer Center
Role: Co-Investigator
Duration: 8/2014 - present
 
Title: Soluble CD30 As a Predictor of Treatment Response in Hodgkin Lymphoma
Funding Source: Texas Federation of Business and Professional Women
Role: Principal Investigator
Duration: 7/1/2006 - 6/2013

Last updated: 7/6/2016